Viralytics on track with IV delivery
Wednesday, 25 June, 2008
Viralytics (ASX: VLA) has completed the first step of phase I clinical trials of its oncolytic virus technology, Cavatrak, for stage IV metastatic melanoma.
The safety trial involved each subject receiving an intravenous injection of Cavatrak. No adverse effects were found in the test subjects, the company said.
Viralytics has also been granted clearance to continue the trials with the next patient group. This cohort will receive two injections of the drug seven days apart.
This trial is being run concurrently with another set of clinical trials of late-stage melanoma patients. The subjects in that trial are being given multiple intra-tumoural injections of Cavatrak in doses up to 100 times the original.
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
Customised immune cells used to fight brain cancer
Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...
Elevated blood protein levels predict mortality
Proteins that play key roles in the development of diseases such as cancer and inflammation may...
